Repeatability and response to therapy of dynamic contrast-enhanced Magnetic Resonance Imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting.
<h4>Objectives</h4> <p>To determine the repeatability, and response to therapy, of Dynamic Contrast-Enhanced (DCE) MRI biomarkers of synovitis in hand and wrist of Rheumatoid Arthritis (RA) patients, and in particular the performance of the transfer constant Ktrans, in a multicent...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Springer
2017
|
| _version_ | 1797077006560526336 |
|---|---|
| author | Taylor, P Waterton, J Ho, M Nordenmark, L Jenkins, M DiCarlo, J Guillard, G Roberts, C Buonaccorsi, G Parker, G Bowes, M Peterfy, C Kellner, H |
| author_facet | Taylor, P Waterton, J Ho, M Nordenmark, L Jenkins, M DiCarlo, J Guillard, G Roberts, C Buonaccorsi, G Parker, G Bowes, M Peterfy, C Kellner, H |
| author_sort | Taylor, P |
| collection | OXFORD |
| description | <h4>Objectives</h4> <p>To determine the repeatability, and response to therapy, of Dynamic Contrast-Enhanced (DCE) MRI biomarkers of synovitis in hand and wrist of Rheumatoid Arthritis (RA) patients, and in particular the performance of the transfer constant Ktrans, in a multicentre trial setting</p> <h4>Methods</h4> <p>DCE-MRI and RA MRI scoring (RAMRIS) were performed with meticulous standardisation at baseline, 6 and 24 weeks in a sub-study of fostamatinib monotherapy in reducing synovitis compared with placebo or adalimumab. Analysis employed statistical shape modelling to avoid biased regions-of-interest, kinetic modelling and heuristic analyses. Repeatability was also evaluated.</p> <h4>Results</h4> <p>At early study termination, DCE-MRI data had been acquired from 58 patients in 19 imaging centres. Ktrans intra-subject coefficient of variation (N=14) was 30%. Ktrans change demonstrated inferiority of fostamatinib (N=11) relative to adalimumab (N=10) after 6 weeks (treatment ratio=1.92, p=0.003), and failed to distinguish fostamatinib from placebo (N=10, p=0.79). RAMRIS showed superiority of fostamatinib relative to placebo at 6 weeks (p=0.023), and did not distinguish fostamatinib from adalimumab at either 6 weeks (p=0.175) or 24 weeks (p=0.230).</p> <h4>Conclusion</h4> <p>This demonstrated repeatability of Ktrans, and its ability to distinguish treatment groups, show that DCE-MRI biomarkers are suitable for use in multicentre RA trials.</p> |
| first_indexed | 2024-03-07T00:11:35Z |
| format | Journal article |
| id | oxford-uuid:796c97a0-7d79-497d-9802-12c6cfb740cd |
| institution | University of Oxford |
| last_indexed | 2024-03-07T00:11:35Z |
| publishDate | 2017 |
| publisher | Springer |
| record_format | dspace |
| spelling | oxford-uuid:796c97a0-7d79-497d-9802-12c6cfb740cd2022-03-26T20:37:23ZRepeatability and response to therapy of dynamic contrast-enhanced Magnetic Resonance Imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:796c97a0-7d79-497d-9802-12c6cfb740cdSymplectic Elements at OxfordSpringer2017Taylor, PWaterton, JHo, MNordenmark, LJenkins, MDiCarlo, JGuillard, GRoberts, CBuonaccorsi, GParker, GBowes, MPeterfy, CKellner, H <h4>Objectives</h4> <p>To determine the repeatability, and response to therapy, of Dynamic Contrast-Enhanced (DCE) MRI biomarkers of synovitis in hand and wrist of Rheumatoid Arthritis (RA) patients, and in particular the performance of the transfer constant Ktrans, in a multicentre trial setting</p> <h4>Methods</h4> <p>DCE-MRI and RA MRI scoring (RAMRIS) were performed with meticulous standardisation at baseline, 6 and 24 weeks in a sub-study of fostamatinib monotherapy in reducing synovitis compared with placebo or adalimumab. Analysis employed statistical shape modelling to avoid biased regions-of-interest, kinetic modelling and heuristic analyses. Repeatability was also evaluated.</p> <h4>Results</h4> <p>At early study termination, DCE-MRI data had been acquired from 58 patients in 19 imaging centres. Ktrans intra-subject coefficient of variation (N=14) was 30%. Ktrans change demonstrated inferiority of fostamatinib (N=11) relative to adalimumab (N=10) after 6 weeks (treatment ratio=1.92, p=0.003), and failed to distinguish fostamatinib from placebo (N=10, p=0.79). RAMRIS showed superiority of fostamatinib relative to placebo at 6 weeks (p=0.023), and did not distinguish fostamatinib from adalimumab at either 6 weeks (p=0.175) or 24 weeks (p=0.230).</p> <h4>Conclusion</h4> <p>This demonstrated repeatability of Ktrans, and its ability to distinguish treatment groups, show that DCE-MRI biomarkers are suitable for use in multicentre RA trials.</p> |
| spellingShingle | Taylor, P Waterton, J Ho, M Nordenmark, L Jenkins, M DiCarlo, J Guillard, G Roberts, C Buonaccorsi, G Parker, G Bowes, M Peterfy, C Kellner, H Repeatability and response to therapy of dynamic contrast-enhanced Magnetic Resonance Imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. |
| title | Repeatability and response to therapy of dynamic contrast-enhanced Magnetic Resonance Imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. |
| title_full | Repeatability and response to therapy of dynamic contrast-enhanced Magnetic Resonance Imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. |
| title_fullStr | Repeatability and response to therapy of dynamic contrast-enhanced Magnetic Resonance Imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. |
| title_full_unstemmed | Repeatability and response to therapy of dynamic contrast-enhanced Magnetic Resonance Imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. |
| title_short | Repeatability and response to therapy of dynamic contrast-enhanced Magnetic Resonance Imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. |
| title_sort | repeatability and response to therapy of dynamic contrast enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting |
| work_keys_str_mv | AT taylorp repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT watertonj repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT hom repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT nordenmarkl repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT jenkinsm repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT dicarloj repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT guillardg repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT robertsc repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT buonaccorsig repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT parkerg repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT bowesm repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT peterfyc repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting AT kellnerh repeatabilityandresponsetotherapyofdynamiccontrastenhancedmagneticresonanceimagingbiomarkersinrheumatoidarthritisinalargemulticentretrialsetting |